Business Wire

REPLY

22.11.2021 09:32:03 CET | Business Wire | Press release

Share
REPLY: Reply’s Hybrid Work Research Confirms that “Hybrid work is not a passing trend”, as it Focuses on the Rapid Evolution of Technologies Designed to Support the New Ways of Working

Increased productivity and advanced collaboration are only two of the benefits the new hybrid work models bring and will soon be the new normal in the business world. This is precisely the outcome from the new Hybrid Work research carried with Reply’s Trend SONAR, the proprietary trend detection and monitoring platform based on Artificial Intelligence - with the support of PAC (Teknowlogy Group).

The research estimated the main market trends using sector studies and evidence collected from Reply customers. Data from two different clusters of countries were then compared: the “Europe-5” (Italy, Germany, France, the Netherlands, Belgium) and the “Big-5” (USA, United Kingdom, Brazil, China, India). The aim was to understand the maturity of the market after the spent year and a half of pandemic life.

Companies that have accelerated their digital transformation during the pandemic define the hybrid work model as popular, effective and performing –the very reasons why there will be no turning back.

Aside from a few limitations related to remote collaboration, which technological innovation will increasingly be able to minimise, the new normal does not provide for a full-time return to physical workplaces as before, but rather for greater flexibility and hybrid work paradigms. This approach is expected to revolutionise office design, corporate culture and the overall employee experience. This scenario will benefit employees with better work-life balance and increase of work efficiency, as well as companies: smaller office spaces, flexible working hours, hiring of talent without the need for relocation.

As Filippo Rizzante, Reply CTO, mentions: “The digital world and technology have reshaped the future of the employee experience. Regardless of the specific working context, be it an office or a factory, hybrid work will increasingly be characterised by the support and collaboration of software or hardware based on artificial intelligence. This will be facilitated by greater data literacy and a propensity for digitisation which will not only be the prerogative of developers, but will instead play a key role for the entire workforce. The transition to remote and flexible working models will, to a certain extent, become a permanent fixture and the new corporate culture will have to welcome and embrace the digital dimension as an integral part of daily work routines, facilitating social connections and communication on site, as well as remotely. What’s more, themes such as sustainability and employee well-being will increasingly become an integral part of a company’s DNA.”

To enable the hybrid work scenario, information must be accessible in the cloud and seamless and instant collaboration must be made possible through the adoption of the right tools for each business and activity. At the infrastructure level, cloud computing is not just an option, it is becoming the standard that is driving hybrid architectures. Spending on public and private cloud technologies already represents more than half of the current global infrastructure spending and this is expected to reach two thirds by 2024.

This acceleration and migration is also fuelling investments in productivity tools that consist mostly of cloud-based and intelligent technologies. Reply’s study highlights that among the Europe-5 countries, this market is expected to reach €7.6 billion by 2025. The push towards cloud computing will also drive the market of the countries that make up the Big-5 cluster, which are expected to reach a market of €36 billion.

Another trend highlighted by Reply’s research is the growth of hyperautomation; another approach based on Artificial Intelligence which extends the use of automation to value-added activities. By 2025, nearly half of the largest global companies are expected to support workers with smart technologies designed to assist with complex interactions.

Cybersecurity is also one of the main enabling technologies for hybrid work, precisely because one of the greatest obstacles to this type of work is the potential vulnerability of corporate networks. For this very reason, security is one of the major investment areas in 2021 and it is not expected to be a short-lived trend. It is estimated that by 2025 the market for end-user device security, in other words security solutions for PCs, smartphones, tablets and other corporate devices, will grow by 45% among the Big-5 countries and by 34% among the Europe-5 countries.

A strong focus on sustainability accompanies the Hybrid Work model: Reply’s research shows that the workforce, and in particular the new generations, search for companies that operate with a solid purpose, that act in a responsible and sustainable manner from an environmental point of view and that have the courage to take a stand in social and cultural debates - with clear and measurable corporate ESG standards. The well-being of the workforce, mental health and quality of life are gaining more relevance in the hybrid work environment, alongside physical safety.

Hybrid work has become an essential factor in retaining talent and when facing the great resignation phenomenon, with almost half of under 35s who, according to global data, are considering quitting their jobs if forced to return to the office full time. As the business landscape continues to change, organisations need to improve their existing capabilities and provide access to distance learning platforms. It is estimated that the Big-5’s spending on online learning platforms will increase by 48% by 2025 , reaching €16 billion, while among the Europe-5s this value will reach €2 billion.

The full research can be downloaded here . This new research is part of the Reply Market Research series, which includes the research papers on “From Cloud to Edge” , “Industrial IoT: a reality check” e “Beyond Digital Marketing ”.

Reply
Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com

Link:

ClickThru

Social Media:

https://www.facebook.com/ReplyinUK/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye